Benefits and Applications of Oncotype DX Breast Recurrence Score Testing among Breast Cancer Patients: Current Recommendations and Controversies.

Abstract

Oncotype DX Breast Recurrence Score is a prognostic and predictive assay of 21 genes, initially designed for therapy planning in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, lymph node-negative or lymph node-positive (maximum 3 nodes involved), early-stage breast cancer. The assay is predictive for 9-year risk of distant recurrence and its role in estimating chemotherapy benefit has been established through several clinical trials. We hereby aimed to review Oncotype DX testing from its initial implementation to the actual clinical setting. In addition, we revise some of the most clinically relevant studies that led to its incorporation into the international breast cancer guidelines.